CEO's Stake Diluted to 8.44% Following Recent Private Placement
INDP has more than doubled off its 52-week low of $0.92 on light trading volume (0.1× avg).
Summary
CEO Junyi Dai's ownership stake in Indaptus Therapeutics has been diluted to 8.44% following the company's recent $12 million private placement, reflecting the impact of capital raises on major shareholders.
Key Events · Ownership and Investor Activity · INDP
-
CEO's Stake Diluted
Junyi Dai's beneficial ownership decreased from 9.45% to 8.44% of common stock, now holding 11,250,000 shares.
-
Dilution Event
The decrease is a direct result of the company's $12 million private placement on June 24, 2026, which significantly increased the number of outstanding shares.
-
No Insider Sale
Mr. Dai did not sell any shares; the change is purely due to company-level dilution from the recent capital raise.
-
Significant Holding Maintained
Despite the dilution, Mr. Dai, as CEO and Chairman, still holds a substantial 8.44% stake in the company.
Analysis · INDP · Life Sciences
This Schedule 13D/A reports that CEO and Chairman Junyi Dai's beneficial ownership in Indaptus Therapeutics has decreased from 9.45% to 8.44%. This reduction is solely due to the significant increase in outstanding shares from the company's recent $12 million private placement on June 24, 2026, not from any sale by Mr. Dai. The filing highlights the dilutive impact of the company's capital raising efforts on major shareholders, including its CEO, as the company navigates a challenging financial period.
At the time of this filing, INDP was trading at $3.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $386.2M. The 52-week trading range was $0.92 to $13.44. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.